Goetz Partners: goetzpartners advised Vivoryon Therapeutics AG on the option agreement and equity commitment for its lead compound to MorphoSys AG

VIVORYON THERAPEUTICS AG, the Germany-based clinical stage precision medicine company focused on novel therapies for age-related diseases, mandated goetzpartners as exclusive advisor on the option agreement of its small molecule inhibitors to MorphoSys AG, the clinical-stage biopharmaceutical company focused on the development of antibodies. MorphoSys obtained an exclusive and worldwide option to license VIVORYON's small [...]